Company intelligence / Profile preview

Simcere Pharmaceutical

Ownership: Private
Employees: ~6584
Development stage: Other

Overview

Simcere and its subsidiaries have over 60 innovative drugs in their pipeline with eight commercialized innovative drugs as of early 2025. The company has multiple programs at NDA/BLA stage and several at Phase III clinical trials. Notable recent approvals include COSELA® localization for commercial supply in China.

Therapeutic areas: NeurologyInfectious DiseasesOncologyImmunologyCardiovascular
Modalities: Monoclonal antibodyBispecific monoclonal antibodyFusion proteinAntibody-drug conjugateSmall molecule
Industry: Biotech

Partnerships

Multiple strategic partnerships with multinational companies and biotechnology enterprises for R&D collaboration and commercialization agreementsShenzhen TargetRx for TGRX‑326 commercialization rights

Beyond the preview

Go deeper on Simcere Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcere Pharmaceutical.

Explore the full profile